Promise around Eli Lilly's expected obesity drug, great earnings adds some $60 billion in market cap

In addition to strong earnings, Eli Lilly's prospects were brightened by encouraging trial results from its obesity-drug competitor Novo Nordisk.

from US Top News and Analysis https://ift.tt/ywxUivJ
https://ift.tt/JRfz9mZ